NEW YORK, NY--(Marketwire - Mar 12, 2012) - The anticoagulant market continues to skyrocket as an aging population requires prevention from stroke and systemic embolism. While Warfarin has long dominated the anticoagulant market, several pharmaceutical companies are researching and developing new types of drugs that do not carry the same risks for uncontrolled bleeding as Warfarin to compete in the stroke prevention market. Five Star Equities examines the outlook for companies in the Healthcare sector and provides equity research on Pfizer Inc. (NYSE: [ PFE ]) and Bristol-Myers Squibb Co. (NYSE: [ BMY ]). Access to the full company reports can be found at:

[ www.fivestarequities.com/PFE ]

[ www.fivestarequities.com/BMY ]

According to a report released by Global Industry Analysts, Inc., the global anticoagulants market is projected to surpass $11.2 billion by the year 2015, driven by an aging global population, rising incidence of cardiovascular diseases, cancers, and acute hip and knee complications, as well as emergence of innovative therapeutics targeting new and previously targeted clotting factors.

Irena Melnikova, PhD, an analyst with TVM Capital in Boston, Massachusetts, wrote in Nature Reviews that the growth in anti-coagulants is being driven by the aging population, increased incidence of cardiovascular disease, and the availability of new medications.

Five Star Equities releases regular market updates on the Healthcare sector so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at [ www.fivestarequities.com ] and get exclusive access to our numerous stock reports and industry newsletters.

Earlier this year, the National Institute for Health and Clinical Excellence recommended use of Bristol-Myers Squibb and Pfizer's Eliquis (apixaban) for the prevention of venous thromboembolism in adults who have undergone total hip replacement or total knee replacement surgery. Currently, analysts surveyed by Thomson Reuters Pharma expect 2015 sales of $1.6 billion for Eliquis.

"It is another dagger in the heart for Warfarin as an anticoagulation treatment for patients with atrial fibrillation to prevent stroke," said Dr Ralph Brindis, a senior adviser for Northern California Kaiser Permanente and immediate past president of the American College of Cardiology, referring to Eliquis.

Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: [ www.fivestarequities.com/disclaimer ]